Oncology Drugs
So pleased (& a little proud) to see U.S. FDA approval of Enzalutamide & Talazoparib in HRR-deficient 1L mCRPC
Photo from Arun Azad/Twitter

So pleased (& a little proud) to see U.S. FDA approval of Enzalutamide & Talazoparib in HRR-deficient 1L mCRPC

In a post by Arun Azad on Twitter, it says, “So pleased (& a little proud) to see U.S. FDA approval of Enzalutamide & Talazoparib in HRR-deficient 1L mCRPC. Impressive rPFS & OS data in this population (see Table). A big win for a lot of pts as approx. 25% of 1L mCRPC pts are HRR-deficient.”

Source: Arun Azad/Twitter

Arun Azad cancer Drugs Enzalutamide Talazoparib U.S. FDA